117P Three-year invasive disease-free survival results from a phase II study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
Ting Luo(Third Affiliated Hospital of Guangzhou Medical University), Deyou Zheng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jiaping Chen(Capital Medical University), Ping He(Sichuan University), Kai Zhu(Taishan Medical University), Xi Yan(Sichuan University), Xiaoyan Zhong(Sichuan University), B. J. Wei(Sichuan University), Taoran Tian(Sichuan University)
Cited by 0
Related Papers
Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance
|Clinical Cancer Research|2021|420
Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice
|Nature|2015|380
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
|Nature|2015|251